vs
CorMedix Inc.（CRMD）与ROGERS CORP（ROG）财务数据对比。点击上方公司名可切换其他公司
ROGERS CORP的季度营收约是CorMedix Inc.的1.6倍（$200.5M vs $128.6M），CorMedix Inc.自由现金流更多（$92.7M vs $1.1M）
CorMedix Inc.是一家处于商业阶段的生物制药企业，专注于开发及商业化用于预防和治疗感染性、炎症性及心肾疾病的创新治疗产品，核心管线针对导管相关血流感染，主要服务北美、欧洲的重症监护及长期透析患者群体。
罗杰斯公司是一家专注于特种工程材料研发生产的企业，总部位于美国亚利桑那州钱德勒市，其产品广泛应用于先进电子、移动通信、清洁能源、航空航天等多个高科技领域，为全球客户提供高性能材料解决方案。
CRMD vs ROG — 直观对比
营收规模更大
ROG
是对方的1.6倍
$128.6M
自由现金流更多
CRMD
多$91.6M
$1.1M
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $128.6M | $200.5M |
| 净利润 | — | $4.5M |
| 毛利率 | 83.4% | 32.2% |
| 营业利润率 | 46.0% | — |
| 净利率 | — | 2.2% |
| 营收同比 | — | 5.2% |
| 净利润同比 | — | 421.4% |
| 每股收益（稀释后） | $0.20 | $0.25 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CRMDROG
| Q1 26 | — | $200.5M | ||
| Q4 25 | $128.6M | $201.5M | ||
| Q3 25 | $104.3M | $216.0M | ||
| Q2 25 | $39.7M | $202.8M | ||
| Q1 25 | $39.1M | $190.5M | ||
| Q4 24 | — | $192.2M | ||
| Q3 24 | — | $210.3M | ||
| Q2 24 | — | $214.2M |
净利润CRMDROG
| Q1 26 | — | $4.5M | ||
| Q4 25 | — | $4.6M | ||
| Q3 25 | $108.6M | $8.6M | ||
| Q2 25 | $19.8M | $-73.6M | ||
| Q1 25 | $20.6M | $-1.4M | ||
| Q4 24 | — | $-500.0K | ||
| Q3 24 | — | $10.7M | ||
| Q2 24 | — | $8.1M |
毛利率CRMDROG
| Q1 26 | — | 32.2% | ||
| Q4 25 | 83.4% | 31.5% | ||
| Q3 25 | 89.3% | 33.5% | ||
| Q2 25 | 95.3% | 31.6% | ||
| Q1 25 | 95.9% | 29.9% | ||
| Q4 24 | — | 32.1% | ||
| Q3 24 | — | 35.2% | ||
| Q2 24 | — | 34.1% |
营业利润率CRMDROG
| Q1 26 | — | — | ||
| Q4 25 | 46.0% | 3.5% | ||
| Q3 25 | 49.2% | 7.3% | ||
| Q2 25 | 49.2% | -33.3% | ||
| Q1 25 | 51.5% | -0.2% | ||
| Q4 24 | — | -6.6% | ||
| Q3 24 | — | 6.9% | ||
| Q2 24 | — | 5.3% |
净利率CRMDROG
| Q1 26 | — | 2.2% | ||
| Q4 25 | — | 2.3% | ||
| Q3 25 | 104.1% | 4.0% | ||
| Q2 25 | 49.9% | -36.3% | ||
| Q1 25 | 52.8% | -0.7% | ||
| Q4 24 | — | -0.3% | ||
| Q3 24 | — | 5.1% | ||
| Q2 24 | — | 3.8% |
每股收益（稀释后）CRMDROG
| Q1 26 | — | $0.25 | ||
| Q4 25 | $0.20 | $0.20 | ||
| Q3 25 | $1.26 | $0.48 | ||
| Q2 25 | $0.28 | $-4.00 | ||
| Q1 25 | $0.30 | $-0.08 | ||
| Q4 24 | — | $-0.04 | ||
| Q3 24 | — | $0.58 | ||
| Q2 24 | — | $0.44 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $148.5M | $195.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $405.3M | $1.2B |
| 总资产 | $826.1M | $1.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CRMDROG
| Q1 26 | — | $195.8M | ||
| Q4 25 | $148.5M | $197.0M | ||
| Q3 25 | $55.7M | $167.8M | ||
| Q2 25 | $190.7M | $157.2M | ||
| Q1 25 | $77.5M | $175.6M | ||
| Q4 24 | — | $159.8M | ||
| Q3 24 | — | $146.4M | ||
| Q2 24 | — | $119.9M |
股东权益CRMDROG
| Q1 26 | — | $1.2B | ||
| Q4 25 | $405.3M | $1.2B | ||
| Q3 25 | $374.1M | $1.2B | ||
| Q2 25 | $220.6M | $1.2B | ||
| Q1 25 | $114.9M | $1.3B | ||
| Q4 24 | — | $1.3B | ||
| Q3 24 | — | $1.3B | ||
| Q2 24 | — | $1.3B |
总资产CRMDROG
| Q1 26 | — | $1.4B | ||
| Q4 25 | $826.1M | $1.4B | ||
| Q3 25 | $750.9M | $1.4B | ||
| Q2 25 | $252.6M | $1.5B | ||
| Q1 25 | $149.6M | $1.5B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | $1.5B | ||
| Q2 24 | — | $1.5B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $94.5M | $5.8M |
| 自由现金流经营现金流 - 资本支出 | $92.7M | $1.1M |
| 自由现金流率自由现金流/营收 | 72.1% | 0.5% |
| 资本支出强度资本支出/营收 | 1.3% | 2.3% |
| 现金转化率经营现金流/净利润 | — | 1.29× |
| 过去12个月自由现金流最近4个季度 | $172.8M | $70.1M |
8季度趋势，按日历期对齐
经营现金流CRMDROG
| Q1 26 | — | $5.8M | ||
| Q4 25 | $94.5M | $46.9M | ||
| Q3 25 | $30.9M | $28.9M | ||
| Q2 25 | $30.0M | $13.7M | ||
| Q1 25 | $19.7M | $11.7M | ||
| Q4 24 | — | $33.7M | ||
| Q3 24 | — | $42.4M | ||
| Q2 24 | — | $22.9M |
自由现金流CRMDROG
| Q1 26 | — | $1.1M | ||
| Q4 25 | $92.7M | $42.2M | ||
| Q3 25 | $30.4M | $21.2M | ||
| Q2 25 | $30.0M | $5.6M | ||
| Q1 25 | $19.7M | $2.1M | ||
| Q4 24 | — | $18.3M | ||
| Q3 24 | — | $25.2M | ||
| Q2 24 | — | $8.8M |
自由现金流率CRMDROG
| Q1 26 | — | 0.5% | ||
| Q4 25 | 72.1% | 20.9% | ||
| Q3 25 | 29.1% | 9.8% | ||
| Q2 25 | 75.4% | 2.8% | ||
| Q1 25 | 50.5% | 1.1% | ||
| Q4 24 | — | 9.5% | ||
| Q3 24 | — | 12.0% | ||
| Q2 24 | — | 4.1% |
资本支出强度CRMDROG
| Q1 26 | — | 2.3% | ||
| Q4 25 | 1.3% | 2.3% | ||
| Q3 25 | 0.5% | 3.6% | ||
| Q2 25 | 0.1% | 4.0% | ||
| Q1 25 | 0.0% | 5.0% | ||
| Q4 24 | — | 8.0% | ||
| Q3 24 | — | 8.2% | ||
| Q2 24 | — | 6.6% |
现金转化率CRMDROG
| Q1 26 | — | 1.29× | ||
| Q4 25 | — | 10.20× | ||
| Q3 25 | 0.28× | 3.36× | ||
| Q2 25 | 1.51× | — | ||
| Q1 25 | 0.96× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 3.96× | ||
| Q2 24 | — | 2.83× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CRMD
| Acquisition Of Melinta | $52.9M | 41% |
| Melinta Portfolio | $45.5M | 35% |
| Other | $18.6M | 14% |
| Contract Revenue | $7.4M | 6% |
| BARDA Agreement | $4.2M | 3% |
ROG
暂无分部数据
